Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
Author:
Funder
Sheba Multiple Sclerosis Center
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Link
https://link.springer.com/content/pdf/10.1007/s00415-022-11030-0.pdf
Reference21 articles.
1. Longbrake EE, Cross AH (2016) Effect of multiple sclerosis disease-modifying therapies on B cells and humoral immunity. JAMA Neurol 73:219–225. https://doi.org/10.1001/jamaneurol.2015.3977
2. Schweitzer F, Laurent S, Fink GR, Barnett MH, Hartung HP, Warnke C (2021) Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. J Neurol 268(7):2379–2389. https://doi.org/10.1007/s00415-019-09690-6
3. Miyazaki Y, Niino M, Fukazawa T, Takahashi E, Nonaka T, Amino I, Tashiro J, Minami N, Fujiki N, Doi S, Kikuchi S (2014) Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations. Clin Immunol 151(2):127–135. https://doi.org/10.1016/j.clim.2014.02.001
4. Huber JE, Chang Y, Meinl I, Kümpfel T, Meinl E, Baumjohann D (2020) Fingolimod profoundly reduces frequencies and alters subset composition of circulating T follicular helper cells in multiple sclerosis patients. J Immunol 204(5):1101–1110. https://doi.org/10.4049/jimmunol.1900955
5. Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, Gurevich M (2021) Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14:17562864211012836. https://doi.org/10.1177/17562864211012835
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study;Frontiers in Immunology;2024-08-19
2. Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis;Clinical Neurology and Neurosurgery;2024-08
3. Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination;Frontiers in Immunology;2024-07-15
4. Long-Term Observation of SARS-CoV-2 Vaccination Response upon High Efficacy Treatment in Multiple Sclerosis—A Real-World Scenario;Vaccines;2024-03-12
5. Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review;Annals of Clinical and Translational Neurology;2024-02-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3